论文部分内容阅读
目的:比较多西紫杉醇与紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌的疗效。方法:选择2006年6月至2012年6月我院收治的宫颈癌晚期患者180例作为研究对象,依据随机数字表将患者分为紫杉醇组(n=90)和多西紫杉醇组(n=90),两组患者在放疗基础上分别接受紫杉醇135 mg/m~2,每周1次,多西紫杉醇25 mg/m~2,每周1次,4周一疗程,维持两个疗程,比较两组患者的近期疗效、生存时间和毒副作用发生情况。结果:紫杉醇和多西紫杉醇组近期治疗的总有效率分别为81.11%和87.78%,差异无统计学意义(P=0.217);且均未出现进展期的病例。紫杉醇组3年生存率为58.89%,明显低于多西紫杉醇组的75.56%,差异有统计学意义(P=0.017);紫杉醇组骨髓抑制和消化道反应的发生率分别为35.56%和37.78%,明显高于多西紫杉醇组的22.22%和26.67%,差异有统计学意义(均P<0.05)。结论:多西紫杉醇联合顺铂同步放化疗治疗晚期宫颈癌能显著提高患者3年生存率,降低毒副作用发生率,且用药量更少,相对安全、合理,患者可耐受,值得进一步临床研究。
Objective: To compare the efficacy of docetaxel and paclitaxel combined with cisplatin concurrent chemoradiotherapy in the treatment of advanced cervical cancer. Methods: One hundred and eighty patients with advanced cervical cancer admitted to our hospital from June 2006 to June 2012 were enrolled in this study. Patients were divided into paclitaxel group (n = 90) and docetaxel group (n = 90) according to random number table ), Two groups received radiotherapy based on paclitaxel 135 mg / m ~ 2, once a week, docetaxel 25 mg / m ~ 2, once a week, 4 weeks of treatment, to maintain two courses, compare two Group of patients with short-term efficacy, survival time and side effects. Results: The total effective rates of short-term treatment with paclitaxel and docetaxel were 81.11% and 87.78% respectively, with no significant difference (P = 0.217). No advanced cases were observed. The 3-year survival rate of paclitaxel group was 58.89%, which was significantly lower than 75.56% of docetaxel group (P = 0.017). The incidences of myelosuppression and gastrointestinal reaction in paclitaxel group were 35.56% and 37.78% , Significantly higher than docetaxel group 22.22% and 26.67%, the difference was statistically significant (P <0.05). Conclusions: Combination of docetaxel and cisplatin concurrent chemoradiotherapy for advanced cervical cancer can significantly improve the 3-year survival rate, reduce the incidence of toxic and side effects, and the dosage is less, relatively safe and reasonable, the patient is tolerable, worthy of further clinical study .